Role of phosphodiesterase-4 inhibitors in chronic obstructive pulmonary disease

키워드

참고문헌 (41)

1. 김창환, "Direct and Indirect Costs of Chronic Obstructive Pulmonary Disease in Korea", Tuberculosis and Respiratory Diseases, 82(1), pp.27~34 (2019), 대한결핵및호흡기학회
2. 이진국, "Old Friends, Old Wine, and Old COPD Classification Are Best", Tuberculosis and Respiratory Diseases, 81(4), pp.347~348 (2018), 대한결핵및호흡기학회
3. Giembycz MA, "Development status of second generation PDE4 inhibitors for asthma and COPD : the story so far", Monaldi Arch Chest Dis, 57, pp.48~64 (2002)
4. Grootendorst DC, "Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD", Thorax, 62, pp.1081~1087 (2007)
5. Wells JM, "A randomized, placebo-controlled trial of roflumilast : effect on proline-glycine-proline and neutrophilic inflammation in chronic obstructive pulmonary disease", Am J Respir Crit Care Med, 192, pp.934~942 (2015)
6. Giembycz MA, "How phosphodiesterase 4inhibitors work in patients with chronic obstructive pulmonary disease of the severe, bronchitic, frequent exacerbator phenotype", Clin Chest Med, 35, pp.203~217 (2014)
7. Sanz MJ, "Roflumilast inhibits leukocyte-endothelial cell interactions, expression of adhesion molecules and microvascular permeability", Br J Pharmacol, 152, pp.481~492 (2007)
8. Dunne AE, "Direct inhibitory effect of the PDE4 inhibitor roflumilast on neutrophil migration in chronic obstructive pulmonary disease", Am J Respir Cell Mol Biol, 60, pp.445~453 (2019)
9. Kesimer M, "Airway mucin concentration as a marker of chronic bronchitis", N Engl J Med, 377, pp.911~922 (2017)
10. Lambert JA, "Cystic fibrosis transmembrane conductance regulator activation by roflumilast contributes to therapeutic benefit in chronic bronchitis", Am J Respir Cell Mol Biol, 50, pp.549~558 (2014)
11. Schmid A, "Roflumilast partially reverses smoke-induced mucociliary dysfunction", Respir Res, 16, pp.135~ (2015)
12. Mata M, "Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells", Thorax, 60, pp.144~152 (2005)
13. Barnes PJ, "Mechanisms and resistance in glucocorticoid control of inflammation", J Steroid Biochem Mol Biol, 120, pp.76~85 (2010)
14. Milara J, "Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease", J Allergy Clin Immunol, 134, pp.314~322 (2014)
15. Rennard SI, "Reduction of exacerbations by the PDE4 inhibitor roflumilast : the importance of defining different subsets of patients with COPD", Respir Res, 12, pp.18~ (2011)
16. Calverley PM, "Roflumilast in symptomatic chronic obstructive pulmonary disease : two randomised clinical trials", Lancet, 374, pp.685~694 (2009)
17. Martinez FJ, "Determinants of response to roflumilast in severe chronic obstructive pulmonary disease : pooled analysis of two randomized trials", Am J Respir Crit Care Med, 198, pp.1268~1278 (2018)
18. Rabe KF, "Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease(ROBERT) : a 16-week, randomised, placebo-controlled trial", Lancet Respir Med, 6, pp.827~836 (2018)
19. Kim SW, "Effect of roflumilast on airway remodelling in a murine model of chronic asthma", Clin Exp Allergy, 46, pp.754~763 (2016)
20. Martinez FJ, "Effect of roflumilast and inhaled corticosteroid", long-acting β2-agonist on chronic obstructive pulmonary disease exacerbations (RE(2)SPOND): a randomized clinical trial, 2016, pp.194, 559~567
21. Rabe KF, "Effect of roflumilast in patients with severe COPD and a history of hospitalisation", Eur Respir J, 50, pp.1700158~ (2017)
22. Agusti A, "Persistent systemic inflammation is associated with poor clinical outcomes in COPD : a novel phenotype", PLoS One, 7, pp.e37483~ (2012)
23. Fabbri LM, "From COPD to chronic systemic inflammatory syndrome?", Lancet, 370, pp.797~799 (2007)
24. White WB, "Cardiovascular safety in patients receiving roflumilast for the treatment of COPD", Chest, 144, pp.758~765 (2013)
25. Ong WK, "The role of the PDE4D cAMP phosphodiesterase in the regulation of glucagon-like peptide-1 release", Br J Pharmacol, 157, pp.633~644 (2009)
26. Wouters EF, "Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus", J Clin Endocrinol Metab, 97, pp.E1720~E1725 (2012)
27. Wedzicha JA, "Roflumilast : a review of its use in the treatment of COPD", Int J Chron Obstruct Pulmon Dis, 11, pp.81~90 (2016)
28. Garnock-Jones KP, "Roflumilast : a review in COPD", Drugs, 75, pp.1645~1656 (2015)
29. Kim KH, "Risk factors for the discontinuation of roflumilast in patients with chronic obstructive pulmonary disease", Int J Chron Obstruct Pulmon Dis, 12, pp.3449~3456 (2017)
30. 주현수, "Incidence of Adverse Effects and Discontinuation Rate between Patients Receiving 250 Micrograms and 500 Micrograms of Roflumilast: A Comparative Study", Tuberculosis and Respiratory Diseases, 81(4), pp.299~304 (2018), 대한결핵및호흡기학회
31. Watz H, "Use of a 4-week up-titration regimen of roflumilast in patients with severe COPD", Int J Chron Obstruct Pulmon Dis, 13, pp.813~822 (2018)
32. Mackay AJ, "Randomized double-blind controlled trial of roflumilast at acute exacerbations of chronic obstructive pulmonary disease", Am J Respir Crit Care Med, 196, pp.656~659 (2017)
33. Singh D, "Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD", Respir Res, 20, pp.180~ (2019)
34. Moretto N, "CHF6001 I : a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration", J Pharmacol Exp Ther, 352, pp.559~567 (2015)
35. Lea S, "The modulatory effects of the PDE4 inhibitors CHF6001 and roflumilast in alveolar macrophages and lung tissue from COPD patients", Cytokine, 123, pp.154739~ (2019)
36. Myou S, "Bronchodilator effect of inhaled olprinone, a phosphodiesterase 3 inhibitor, in asthmatic patients", Am J Respir Crit Care Med, 160, pp.817~820 (1999)
37. Singh D, "The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD", Eur Respir J, 52, pp.1801074~ (2018)
38. Rabe KF, "Roflumilast : an oral anti-inflammatory treatment for chronic obstructive pulmonary disease : a randomised controlled trial", Lancet, 366, pp.563~571 (2005)
39. Lim JU, "Comparison of World Health Organization and Asia-Pacific body mass index classifications in COPD patients", Int J Chron Obstruct Pulmon Dis, 12, pp.2465~2475 (2017)
40. Jo YS, "Impact of BMI on exacerbation and medical care expenses in subjects with mild to moderate airflow obstruction", Int J Chron Obstruct Pulmon Dis, 13, pp.2261~2269 (2018)
41. Rhee CK, "Management of COPD in Asia : a position statement of the Asian Pacific Society of Respirology", Respirology, 24, pp.1018~1025 (2019)

관련 논문AI추천